These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25962100)

  • 1. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
    Marzolini C; Gibbons S; Khoo S; Back D
    J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
    Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
    J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.
    Capetti A; Cossu MV; Rizzardini G
    Expert Opin Pharmacother; 2015; 16(17):2689-702. PubMed ID: 26612518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.
    Curran A; Pérez-Valero I; Moltó J
    AIDS Rev; 2015; 17(2):114-20. PubMed ID: 26035169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
    Kakuda TN; Brochot A; Tomaka FL; Vangeneugden T; Van De Casteele T; Hoetelmans RM
    J Antimicrob Chemother; 2014 Oct; 69(10):2591-605. PubMed ID: 24951533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
    Deeks ED
    Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.
    Renjifo B; van Wyk J; Salem AH; Bow D; Ng J; Norton M
    AIDS Rev; 2015; 17(1):37-46. PubMed ID: 25586481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children.
    Bastiaans DET; Geelen SPM; Visser EG; van der Flier M; Vermont CL; Colbers APH; Roukens M; Burger DM; van Rossum AMC;
    Pediatr Infect Dis J; 2018 Oct; 37(10):1008-1010. PubMed ID: 29474261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological aspects of darunavir/cobicistat].
    González-Domenech CM; Palacios R; Santos J
    Enferm Infecc Microbiol Clin; 2016 May; 34 Suppl 1():30-33. PubMed ID: 28081761
    [No Abstract]   [Full Text] [Related]  

  • 18. Elvitegravir for the treatment of HIV.
    Unger NR; Worley MV; Kisgen JJ; Sherman EM; Childs-Kean LM
    Expert Opin Pharmacother; 2016 Dec; 17(17):2359-2370. PubMed ID: 27767362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
    Brown K; Patterson-Browning B; Liu C; Patel M; Stewart L; Nettles RE
    Rev Recent Clin Trials; 2017; 12(3):174-181. PubMed ID: 28403798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
    Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
    Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.